Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Medical Oncology
Published in: Medical Oncology 4/2002

01-12-2002 | Case Report

Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia

Authors: Nina Cavalli-Björkman, Eva Ösby, Jeanette Lundin, Mats Kalin, Anders Österborg, Astrid Gruber, MD, PhD

Published in: Medical Oncology | Issue 4/2002

Login to get access
Metadata
Title
Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-CELL chronic lymphocytic leukemia
Authors
Nina Cavalli-Björkman
Eva Ösby
Jeanette Lundin
Mats Kalin
Anders Österborg
Astrid Gruber, MD, PhD
Publication date
01-12-2002
Publisher
Humana Press
Published in
Medical Oncology / Issue 4/2002
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1385/MO:19:4:277

Other articles of this Issue 4/2002

Medical Oncology 4/2002 Go to the issue

Original Article

Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma

Original Article

Clinical significance of nm23 expression and chromosome 17 numerical aberrations in primary gastric cancer

Original Article

Oral ftorafur plus intramuscular thiotepa as adjuvant chemotherapy in patients with breast cancer

Review

Dendritic cell vaccines in the treatment of multiple myeloma

Editorial

Dendritic cells highly quoted on immunotherapy stock market

Case Report

Pancreatic metastasis and extrahepatic biliary obstruction in squamous cell lung carcinoma
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits